6 Meridian Has $8.79 Million Position in Eli Lilly And Co (NYSE:LLY)

6 Meridian grew its stake in Eli Lilly And Co (NYSE:LLY) by 46.2% during the third quarter, HoldingsChannel reports. The firm owned 78,603 shares of the company’s stock after buying an additional 24,823 shares during the quarter. Eli Lilly And Co accounts for about 0.8% of 6 Meridian’s investment portfolio, making the stock its 26th largest holding. 6 Meridian’s holdings in Eli Lilly And Co were worth $8,790,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. CWM LLC boosted its position in Eli Lilly And Co by 46.4% during the 3rd quarter. CWM LLC now owns 180,579 shares of the company’s stock worth $20,194,000 after buying an additional 57,192 shares during the period. Nicolet Bankshares Inc. acquired a new stake in Eli Lilly And Co during the 3rd quarter worth approximately $184,000. Horan Capital Advisors LLC. acquired a new stake in Eli Lilly And Co during the 3rd quarter worth approximately $69,000. Investors Research Corp boosted its position in Eli Lilly And Co by 5.6% during the 3rd quarter. Investors Research Corp now owns 1,764 shares of the company’s stock worth $197,000 after buying an additional 93 shares during the period. Finally, Moors & Cabot Inc. boosted its position in Eli Lilly And Co by 16.0% during the 3rd quarter. Moors & Cabot Inc. now owns 19,239 shares of the company’s stock worth $2,152,000 after buying an additional 2,654 shares during the period. Institutional investors own 76.75% of the company’s stock.

NYSE:LLY opened at $109.84 on Wednesday. The company has a debt-to-equity ratio of 4.98, a current ratio of 1.13 and a quick ratio of 0.87. Eli Lilly And Co has a one year low of $104.17 and a one year high of $132.13. The firm’s 50 day simple moving average is $110.86 and its 200 day simple moving average is $113.62. The company has a market cap of $104.18 billion, a PE ratio of 19.44, a P/E/G ratio of 1.84 and a beta of 0.16.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 30th. The company reported $1.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.05. Eli Lilly And Co had a net margin of 33.76% and a return on equity of 70.86%. The firm had revenue of $5.64 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business earned $1.48 EPS. The company’s revenue was up .9% compared to the same quarter last year. Equities research analysts expect that Eli Lilly And Co will post 5.73 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a yield of 2.35%. Eli Lilly And Co’s payout ratio is 46.49%.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 19,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total transaction of $2,201,745.00. Following the completion of the transaction, the senior vice president now owns 38,306 shares in the company, valued at approximately $4,325,130.46. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Alfonso G. Zulueta sold 4,500 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $117.00, for a total transaction of $526,500.00. Following the transaction, the senior vice president now owns 33,806 shares of the company’s stock, valued at approximately $3,955,302. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 243,452 shares of company stock valued at $28,252,925. Company insiders own 0.11% of the company’s stock.

LLY has been the topic of several recent research reports. Bank of America initiated coverage on shares of Eli Lilly And Co in a research report on Wednesday, October 16th. They set a “buy” rating and a $133.00 target price on the stock. ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Finally, UBS Group cut their target price on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly And Co presently has a consensus rating of “Buy” and a consensus price target of $127.69.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Why is total return important?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.